



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71680

**Title:** Elemene-containing hyperthermic intraperitoneal chemotherapy combined with oxaliplatin and capecitabine chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer: A prospective analysis

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05194798

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Director

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-09-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-04 00:57

**Reviewer performed review:** 2021-10-08 11:32

**Review time:** 4 Days and 10 Hours

|                           |   |
|---------------------------|---|
| <b>Scientific quality</b> | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>         | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |



|                                 |   |
|---------------------------------|---|
| <b>Re-review</b>                | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript is an original article that investigated the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) containing elemene, combined with reduced CapeOx chemotherapy regimens in elderly patients with peritoneal metastatic gastric cancer. The authors showed HIPEC containing elemene with reduced CapeOx chemotherapy attenuated the side effects, such as myelosuppression with the comparable outcomes, compared with the lobaplatin-based regimen. The results will be of interest to clinicians in the field. However, the following major and minor issues require clarification: Major 1. I think this study is prospective but not retrospective as a total of 39 patients were randomly divided into two groups. Therefore, the authors should provide a flow chart of the study process including excluded patients. 2. The authors concluded that the elemene-containing HIPEC combined with CapeOx reduction regimen can extend the overall survival. However, its predominance regarding the OS was not statistically proven in this study. Please reconsider the conclusion. 3. The composition of the contents seems unsophisticated. A kind of methods was described in the Results section, a sentence including discussion was found in the Results section, some contents which should be written in the introduction section were described in the Discussion section, and most description in the conclusion should be written in the Discussion section. Please reconsider them. Minor 1. (Title) Please spell out "HIPEC" and "CapeOx". 2. Please explain why the patients with hypertension were excluded. 3. The authors should provide the data of other treatment before and after these regimens. 4. (Table1) Please provide the data of the performance status. 5.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

(Table 1) "Abdominal infection" is duplicated. 6. (P13L16-17) Please spell out "FLOT4" and "DCF". 7. (Figure 1) Please draw the line of Group M clearly.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71680

**Title:** Elemene-containing hyperthermic intraperitoneal chemotherapy combined with oxaliplatin and capecitabine chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer: A prospective analysis

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03806663

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-09-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-10 09:34

**Reviewer performed review:** 2021-10-12 12:31

**Review time:** 2 Days and 2 Hours

|                           |   |
|---------------------------|---|
| <b>Scientific quality</b> | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>         | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

|                                 |   |
|---------------------------------|---|
| <b>Re-review</b>                | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

### **SPECIFIC COMMENTS TO AUTHORS**

this work is interesting, as it discusses a hot issue, but i have some comments: 1- the sample size is small 2- this is a single center study, you need more randomized multicenter studies to prove the role of Elemene 3- are the pharmacokinetics and pharmacodynamics of elemene well studied?